| DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells YJ He, K Meghani, MC Caron, C Yang, DA Ronato, J Bian, A Sharma, ... Nature 563 (7732), 522-526, 2018 | 194 | 2018 |
| Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13 M Zeng, NP Kwiatkowski, T Zhang, B Nabet, M Xu, Y Liang, C Quan, ... Elife 7, e39030, 2018 | 142 | 2018 |
| Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer YE Choi, K Meghani, ME Brault, L Leclerc, YJ He, TA Day, KM Elias, ... Cell reports 14 (3), 429-439, 2016 | 142 | 2016 |
| TIRR regulates 53BP1 by masking its histone methyl-lysine binding function P Drané, ME Brault, G Cui, K Meghani, S Chaubey, A Detappe, ... Nature 543 (7644), 211-216, 2017 | 126 | 2017 |
| Evolutionarily conserved serum microRNAs predict radiation-induced fatality in nonhuman primates W Fendler, B Malachowska, K Meghani, PA Konstantinopoulos, C Guha, ... Science translational medicine 9 (379), eaal2408, 2017 | 78 | 2017 |
| Multifaceted impact of microRNA 493-5p on genome-stabilizing pathways induces platinum and PARP inhibitor resistance in BRCA2-mutated carcinomas K Meghani, W Fuchs, A Detappe, P Drané, E Gogola, S Rottenberg, ... Cell reports 23 (1), 100-111, 2018 | 71 | 2018 |
| First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Guérin K Meghani, LF Cooley, B Choy, M Kocherginsky, S Swaminathan, ... European urology 82 (6), 602-610, 2022 | 34 | 2022 |
| Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer AG Robertson, K Meghani, LF Cooley, KA McLaughlin, LA Fall, Y Yu, ... Nature communications 14 (1), 2126, 2023 | 18 | 2023 |
| Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma A Piunti, K Meghani, Y Yu, AG Robertson, JR Podojil, KA McLaughlin, ... Science advances 8 (40), eabo8043, 2022 | 17 | 2022 |
| Biodegradable nanoparticles induce cGAS/STING-dependent reprogramming of myeloid cells to promote tumor immunotherapy JR Podojil, AC Cogswell, MY Chiang, V Eaton, I Ifergan, T Neef, D Xu, ... Frontiers in immunology 13, 887649, 2022 | 6 | 2022 |
| Role of chromatin modifying complexes and therapeutic opportunities in bladder cancer K Meghani, L Folgosa Cooley, A Piunti, JJ Meeks Bladder Cancer 8 (2), 101-112, 2022 | 5 | 2022 |
| Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment Z Zhao, Y Aoi, CN Philips, KA Meghani, SR Gold, Y Yu, LS John, J Qian, ... Proceedings of the National Academy of Sciences 120 (52), e2310063120, 2023 | 3 | 2023 |
| Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer K Meghani, N Frydenlund, Y Yu, B Choy, JJ Meeks Journal for immunotherapy of cancer 12 (4), 2024 | 1 | 2024 |
| Abstract GMM-027: DYNLL1 INHIBITS DNA END RESECTION IN BRCA1-DEFICIENT CELLS AND REGULATES PARP INHIBITOR SENSITIVITY YJ He, K Meghani, MC Caron, C Yang, DA Ronato, J Bian, A Sharma, ... Clinical Cancer Research 25 (22_Supplement), GMM-027-GMM-027, 2019 | 1 | 2019 |
| Abstract PR011: Imaging mass cytometry captures patient heterogeneity enabling BCG response stratification in non-muscle invasive bladder cancer AF Pour, D Baker, S Sivajothi, B Choy, K Meghani, Y Yu, LA Fall, B Ristau, ... Clinical Cancer Research 30 (10_Supplement), PR011-PR011, 2024 | | 2024 |
| Biodegradable nanoparticle-induced sting pathway activation for the treatment of cancer. J Podojil, A Cogswell, MY Chiang, V Eaton, I Efergan, T Neef, D Xu, ... Journal of Clinical Oncology 40 (16_suppl), e14552-e14552, 2022 | | 2022 |
| PD12-06 DIFFERENTIAL MYELOID INFLAMMATORY RESPONSE AND TUMORIGENESIS BY GENDER IN MOUSE MODEL OF BLADDER CANCER LF Cooley, J Podojil, K Meghani, Y Yu, S Miller, J Meeks The Journal of Urology 207 (Supplement 5), e197, 2022 | | 2022 |
| PD42-08 DIFFERENTIAL MYELOID DERIVED SUPPRESSOR CELL RECRUITMENT AND TUMORIGENESIS BY GENDER IN MOUSE MODEL OF BLADDER CANCER LF Cooley, J Podojil, K Meghani, Y Yu, SD Miller, JJ Meeks Journal of Urology 206 (Supplement 3), e727, 2021 | | 2021 |
| DYNLL1 INHIBITS DNA END RESECTION IN BRCA1-DEFICIENT CELLS AND REGULATES PARP INHIBITOR SENSITIVITY YJ He, K Meghani, MC Caron, C Yang, DA Ronato, J Bian, A Sharma, ... CLINICAL CANCER RESEARCH 25 (22), 90-90, 2019 | | 2019 |
| MicroRNA profiling to identify novel determinants of platinum resistance in BRCA1/2-mutated high-grade serous ovarian cancer K Meghani, E Gogola, S Rottenberg, J Jonkers, U Matulonis, E Swisher, ... CANCER RESEARCH 77, 2017 | | 2017 |
